Listen: Pharma's lobbying dollars & diversity in Covid-19 studies - STAT

Listen: Pharma's lobbying dollars & diversity in Covid-19 studies - STAT

Listen: Pharma’s lobbying dollars, Alnylam’s future, and diversity in Covid-19 studies

By DAMIAN GARDE AND REBECCA ROBBINS AND ADAM FEUERSTEIN

STAT's Lev Facher joins us in this episode to talk about Sen. Kamala Harris' health care record and how pharma is spending its lobbying dollars in 2020.

READ MORE